Sign In
Buy BNTX
$88.45
-0.690 (-0.774%)
At Close: Jun 03, 2026
BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
05:26pm, Tuesday, 20'th Aug 2024
Partial clinical hold of BioNTech SE's BNT326/YL202 for the treatment of patients with solid tumors in phase 1 study was lifted by the FDA. The primary endpoint of ORR of BNT111 in combination with Li
BioNTech says FDA lifts partial hold on its cancer drug trial
06:59am, Monday, 19'th Aug 2024
BioNTech on Monday said the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on an early stage study of its experimental cancer drug.
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
04:07am, Monday, 19'th Aug 2024
Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to achieve
Pfizer, BioNTech Combination Flu and COVID-19 Shot Misses 1 of 2 Endpoints
02:28pm, Friday, 16'th Aug 2024
Shares of Pfizer (PFE) and American depositary receipts (ADRs) of BioNTech (BNTX) dropped in intraday trading Friday following disappointing results from a late-stage study of the drugmakers' combined
Pfizer, BioNTech COVID-19-flu combination drug meets 1 of 2 trial objectives
07:01am, Friday, 16'th Aug 2024
Pfizer Inc. PFE, -0.59% and BioNTech SE BNTX, +2.83% said Friday a Phase 3 trial of their COVID-19-influenza vaccine candidate met one of its two objectives. The companies said the candidate showed �
Pfizer, BioNtech say combined flu-COVID vaccine misses a main goal of Phase 3 trial
06:51am, Friday, 16'th Aug 2024
Pfizer and BioNTech said a late-stage trial of their experimental mRNA vaccine to protect against influenza and COVID-19 found the combination shot failed to meet one of the study's two main goals and
NEW YORK and MAINZ, Germany, August 16, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial
3 Biotech Stocks With Promising Drug Pipelines: August 2024
06:40am, Thursday, 08'th Aug 2024
Investing in biotech stocks with promising pipelines has to be the most exciting area of the market. A successful drug approval can not only unveil a blockbuster treatment worth billions of dollars, b
BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
11:04am, Tuesday, 06'th Aug 2024
BioNTech SE reported Q2 2024 earnings yesterday, with a significant decrease in revenues from Comirnaty compared to previous years. The company reaffirmed guidance for 2024, for revenues of $2.7bn —
BioNTech SE (BNTX) Q2 2024 Earnings Call Transcript
01:03pm, Monday, 05'th Aug 2024
BioNTech SE (NASDAQ:BNTX ) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Victoria Meissner - Vice President, Strategy & Investor Relations Ugur Sahin - Chief Executiv
BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls
10:46am, Monday, 05'th Aug 2024
American depositary receipts (ADRs) of BioNTech (BNTX) fell Monday after the COVID-19 vaccine maker's second-quarter loss quadrupled on falling demand for the shots, and as it ended an agreement with
Monday, BioNTech SE BNTX reported deeper losses in the second quarter of 2024, with an EPS loss of $(3.62) or (3.36) euros, missing the consensus of (1.89) euros and higher than (79) cents in the s
BioNTech's stock slides 4% after earnings fall short of estimates as COVID vaccine falls slide
06:20am, Monday, 05'th Aug 2024
BioNTech SE's stock BNTX, +1.65% fell 4% early Monday, after the company's second-quarter earnings fell short of estimates amid a continued slide in sales of its COVID-19 vaccine. The company had a ne
BioNTech widens loss to 807.8 mln euro in second quarter
06:02am, Monday, 05'th Aug 2024
Losses at Germany's BioNTech quadrupled year-on-year in the second quarter, the company said on Monday, as it banks on a strategy shift towards new cancer treatments following a sharp drop-off in sale
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
05:59am, Monday, 05'th Aug 2024
Announced positive data from multiple mRNA cancer vaccine clinical trials, including topline results from the ongoing Phase 2 evaluating FixVac candidate BNT111 Launched updated variant-adapted COVID-
